Astec Lifesciences Ltd (ASTEC)

Chemicals · Agro Chemicals · NSE · Updated 3 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹572.3 ↓ 32.8% (1Y)

🎯 Key Takeaways

Astec Lifesciences Ltd is in a turnaround phase, transitioning from sustained losses toward operational stabilization with early signs of margin improvement despite declining revenue. The company has achieved EBITDA breakeven in Q1FY27 and narrowed net losses sequentially, reflecting cost optimization and efficiency gains.
Revenue declined 47.3% QoQ to ₹84 in Q1FY27.
⚠️ Persistent profitability challenges: Despite EBITDA breakeven in Q1FY27, the company continues to report net losses and negative ROE (-17%), indicatin

Market Cap

₹1,275

P/B Ratio

3.26

ROE

-17.0%

ROCE

-4.2%

Debt/Equity

1.15

Promoter

72.0%

✨ Ask AI About ASTEC 📊 Interactive Charts

📖 The Story

Astec Lifesciences Ltd is in a turnaround phase, transitioning from sustained losses toward operational stabilization with early signs of margin improvement despite declining revenue. The company has achieved EBITDA breakeven in Q1FY27 and narrowed net losses sequentially, reflecting cost optimization and efficiency gains. However, persistent negative ROE and ROCE, coupled with high leverage, indicate structural challenges remain. Management is focusing on strategic growth in CDMO and export markets, but profitability remains elusive.

📰 What's Happening

In Q1FY27 (July 2026), Astec reported consolidated revenue of ₹84.3 crore, down 8% YoY, but EBITDA turned positive at ₹0.1 crore from a ₹10.5 crore loss previously, and net loss narrowed to ₹-18.7 crore from ₹-33.0 crore. This improvement occurred despite lower revenue, signaling operational efficiency gains. The company approved unaudited financial results for Q1FY27 in a July 31, 2026 filing, with no specific forward guidance provided. Earlier, in FY2025-26, revenue grew to ₹45,321.65 Lakh, and net loss reduced to ₹8,087.62 Lakh from ₹13,471.17 Lakh, with shareholders approving all AGM resolutions including director re-appointment and cost auditor remuneration. The Board also approved unaudited standalone and consolidated results for Q1FY26 showing a net loss of ₹1,873.84 lakhs. Management emphasized expanding CDMO capabilities, leveraging R&D infrastructure, and capitalizing on global agrochemical market growth, while highlighting sustainability initiatives like EcoVadis Gold rating and 26.7% renewable energy use.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	74	125	159	84
Operating Profit	-17	-7	-3	-12
OPM %	-23.2%	-5.8%	-1.6%	-14.0%
Net Profit	-24	-16	-8	-19
EPS	₹-11.35	₹-7.04	₹-3.48	₹-8.40

Revenue has declined over the past four quarters, from ₹125 crore in Dec 2025 to ₹74 crore in Sep 2025, then to ₹159 crore in Mar 2026 and ₹84.3 crore in Jun 2026, indicating volatility without a clear upward trend. However, operating performance has improved: net loss narrowed from ₹-24 crore in Sep 2025 to ₹-19 crore in Jun 2026, and EBITDA turned positive in Q1FY27 after being negative in prior periods. This suggests cost control measures are yielding results despite revenue pressure. The company achieved EBITDA breakeven in Q1FY27, a key inflection point, and management highlighted margin improvement as a key investor takeaway. While revenue declined YoY, the focus appears to be on profitability and operational resilience rather than top-line growth.

🔮 Management Outlook & What's Next

Management did not provide specific financial guidance in the latest filings, but emphasized strategic expansion in CDMO capabilities, global market growth (projecting 3.4% CAGR to $301.34B by 2033), and sustainability initiatives. In the FY2025-26 annual report, management highlighted leveraging R&D infrastructure and diversifying supply chains to mitigate risks. They also noted progress in safety excellence (94% UA/UC compliance) and ESG commitments, including SBTi targets. No specific revenue, margin, or profitability targets were disclosed beyond existing commitments. The focus remains on operational improvement, export growth, and capitalizing on high-value segments, with an emphasis on governance and stakeholder confidence as reflected in overwhelming shareholder approval at the AGM.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	20	20	22	22
Reserves	272	215	392	368
Borrowings	500	555	367	449
Total Liabilities	882	881	883	942
Fixed Assets	518	497	475	478
Investments	0	0	0	0
Total Assets	882	881	883	942

The balance sheet shows a mixed capital structure with declining borrowings — from ₹555 crore in Mar 2025 to ₹367 crore in Mar 2026 — indicating active deleveraging. Equity remains stable around ₹22 crore, but reserves have increased from ₹215 crore to ₹368 crore, suggesting retained earnings or revaluation benefits are building. Total assets rose to ₹942 crore in Mar 2026 from ₹881 crore in Mar 2025, reflecting growth in operations despite losses. The reduction in debt, coupled with positive cash flow from financing activities (₹94 crore in Mar 2026), suggests the company is managing its capital structure carefully, possibly to support strategic initiatives or fund rights issue proceeds of ₹249.35 crore. However, high leverage (D/E of 1.15) and negative net worth persist, requiring continued financial discipline.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	-81
Investing	-4
Financing	+94
Net Cash Flow	+9

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	72.4%	72.0%	72.0%	72.0%
FII	0.0%	0.0%	0.0%	0.0%
DII	4.0%	3.2%	3.3%	3.3%
Public	19.3%	20.9%	20.8%	20.5%
# Shareholders	18,276	22,293	21,041	19,889

Promoter holding remains stable at ~72% over recent quarters, indicating confidence from the controlling stakeholder. FII holdings are negligible (0.01–0.04%), while DII ownership has slightly increased to 3.33% in Q1FY27 from 3.17% in Q3FY26, suggesting modest institutional interest. The number of public shareholders has grown from 18,276 to 22,293 over four quarters, reflecting retail investor engagement. No pledging or significant dilution is evident. The rights issue raised ₹249.35 crore, which may have been used for debt reduction or strategic investments. Overall, the shareholding pattern shows no signs of exit by promoters or major investors, with governance disclosures confirming no material related party transactions.

⚖️ Peer Comparison — Agro Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
UPL	48,628	23.9	11.4%	6.7%	0.64
PIIND	36,269	31.1	13.3%	10.4%	0.02
SUMICHEM	25,207	43.5	23.1%	17.1%	0.00
BAYERCROP	17,890	370.6	3.3%	1.2%	0.00
SHARDACROP	7,023	11.2	25.8%	20.0%	0.00
DHANUKA	4,432	15.2	27.5%	21.2%	0.03
RALLIS	4,075	24.9	12.9%	9.7%	0.03
NACLIND	3,922	334.9	6.0%	1.8%	0.44
BHAGCHEM	3,474	126.4	6.1%	3.9%	0.33
GSPCROP	2,915	25.5	22.5%	21.9%	0.66

🔗 Peer Stock Analyses

UPL PIIND SUMICHEM BAYERCROP SHARDACROP

⚠️ Risk Factors

1. Persistent profitability challenges: Despite EBITDA breakeven in Q1FY27, the company continues to report net losses and negative ROE (-17%), indicating that cost improvements have not yet translated into sustainable earnings. 2. Revenue volatility: Declining top-line trends across quarters (₹74–159 crore range) without consistent growth raise concerns about demand sustainability and market positioning. 3. High leverage and negative net worth: With D/E at 1.15 and negative equity indicators, financial flexibility is limited, especially amid macroeconomic headwinds. 4. Raw material and export dependency: Management flagged exposure to foreign exchange volatility, trade tensions, and raw material supply chain risks, which could impact margins and global competitiveness.

📋 Recent Filings

🧠 Analyst's Read

Astec Lifesciences is in a fragile turnaround phase, showing early signs of operational improvement but still far from profitability. Investors should monitor whether margin gains can be sustained amid declining revenue and whether the CDMO expansion strategy delivers scalable returns. The next few quarters will be critical to validate the sustainability of cost discipline and the commercial traction of high-growth segments. Watch for updated guidance, margin trends, and export order visibility as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ASTEC

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-03.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ASTEC files new disclosures

Track ASTEC filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ASTEC — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd